At the news
? BEARISHIMPACT 7/10 8-K filed May 15, 2026 at 16:00 ET
Skye Bioscience received a Nasdaq delisting notice on May 13, 2026, for failing to meet the $10M minimum stockholders' equity requirement (reported equity: $9,011,804). The company has 45 days to submit a compliance plan, with a possible 180-day extension to cure. Failure to regain compliance could result in delisting from the Nasdaq Global Market, severely impacting liquidity and institutional ownership.
- Stockholders' equity was $9,011,804 as of March 31, 2026, below the $10,000,000 minimum required by Nasdaq Listing Rule 5450(b)(1)(A).
- Company has until June 29, 2026 to submit a compliance plan to Nasdaq.
- If plan is accepted, Nasdaq may grant an extension until November 9, 2026 to regain compliance.
- No immediate effect on trading; stock continues to trade under symbol SKYE.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access